144 related articles for article (PubMed ID: 36801946)
41. Low humoral and cellular immune responses early after breakthrough infection may contribute to severe COVID-19.
Lee CM; Choe PG; Kang CK; Lee E; Song KH; Bang JH; Kim ES; Kim HB; Kim NJ; Kim HR; Kim Y; Lee CH; Shin HM; Park SW; Park WB; Oh MD
Front Immunol; 2023; 14():1106664. PubMed ID: 37033936
[TBL] [Abstract][Full Text] [Related]
42. SARS-CoV-2 Vaccine Effectiveness and Breakthrough Infections Among Patients Receiving Maintenance Dialysis.
Manley HJ; Li NC; Aweh GN; Hsu CM; Weiner DE; Miskulin D; Harford AM; Johnson D; Lacson E
Am J Kidney Dis; 2023 Apr; 81(4):406-415. PubMed ID: 36462570
[TBL] [Abstract][Full Text] [Related]
43. Clinical and Immunological Features of SARS-CoV-2 Breakthrough Infections in Vaccinated Individuals Requiring Hospitalization.
Lamacchia G; Mazzoni A; Spinicci M; Vanni A; Salvati L; Peruzzi B; Bencini S; Capone M; Carnasciali A; Farahvachi P; Rocca A; Kiros ST; Graziani L; Zammarchi L; Mencarini J; Colao MG; Caporale R; Liotta F; Cosmi L; Rossolini GM; Bartoloni A; Maggi L; Annunziato F
J Clin Immunol; 2022 Oct; 42(7):1379-1391. PubMed ID: 35809212
[TBL] [Abstract][Full Text] [Related]
44. Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study.
Iavarone M; Tosetti G; Facchetti F; Topa M; Er JM; Hang SK; Licari D; Lombardi A; D'Ambrosio R; Degasperi E; Loglio A; Oggioni C; Perbellini R; Caccia R; Bandera A; Gori A; Ceriotti F; Scudeller L; Bertoletti A; Lampertico P
Dig Liver Dis; 2023 Feb; 55(2):160-168. PubMed ID: 36266209
[TBL] [Abstract][Full Text] [Related]
45. SARS-CoV-2 breakthrough infections after COVID-19 vaccination in patients with inflammatory bowel disease: a systematic review and meta-analysis.
van de Pol N; Pan Q; Derikx LAAP; Bakker L; van der Woude CJ; de Vries AC
Therap Adv Gastroenterol; 2023; 16():17562848231174295. PubMed ID: 37461739
[TBL] [Abstract][Full Text] [Related]
46. Breakthrough infections with the SARS-CoV-2 Delta variant: vaccinations halved transmission risk.
Hsu L; Hurraß J; Kossow A; Klobucnik J; Nießen J; Wiesmüller GA; Grüne B; Joisten C
Public Health; 2022 Mar; 204():40-42. PubMed ID: 35152039
[TBL] [Abstract][Full Text] [Related]
47. Humoral and T Cell Immune Responses against SARS-CoV-2 after Primary and Homologous or Heterologous Booster Vaccinations and Breakthrough Infection: A Longitudinal Cohort Study in Malaysia.
Fu JYL; Pukhari MH; Bador MK; Sam IC; Chan YF
Viruses; 2023 Mar; 15(4):. PubMed ID: 37112825
[TBL] [Abstract][Full Text] [Related]
48. SARS-CoV-2-reactive antibody waning, booster effect and breakthrough SARS-CoV-2 infection in hematopoietic stem cell transplant and cell therapy recipients at one year after vaccination.
Piñana JL; Martino R; Vazquez L; López-Corral L; Pérez A; Chorão P; Avendaño-Pita A; Pascual MJ; Sánchez-Salinas A; Sanz-Linares G; Olave MT; Arroyo I; Tormo M; Villalon L; Conesa-Garcia V; Gago B; Terol MJ; Villalba M; Garcia-Gutierrez V; Cabero A; Hernández-Rivas JÁ; Ferrer E; García-Cadenas I; Teruel A; Navarro D; Cedillo Á; Sureda A; Solano C;
Bone Marrow Transplant; 2023 May; 58(5):567-580. PubMed ID: 36854892
[TBL] [Abstract][Full Text] [Related]
49. SARS-CoV-2 humoral and cellular immunity following different combinations of vaccination and breakthrough infection.
Pušnik J; Monzon-Posadas WO; Zorn J; Peters K; Baum M; Proksch H; Schlüter CB; Alter G; Menting T; Streeck H
Nat Commun; 2023 Feb; 14(1):572. PubMed ID: 36732523
[TBL] [Abstract][Full Text] [Related]
50. Incidence and clinical phenotype of multisystem inflammatory syndrome in children after infection with the SARS-CoV-2 delta variant by vaccination status: a Danish nationwide prospective cohort study.
Nygaard U; Holm M; Hartling UB; Glenthøj J; Schmidt LS; Nordly SB; Matthesen AT; von Linstow ML; Espenhain L
Lancet Child Adolesc Health; 2022 Jul; 6(7):459-465. PubMed ID: 35526537
[TBL] [Abstract][Full Text] [Related]
51. A prospective, randomized, single-blinded, crossover trial to investigate the effect of a wearable device in addition to a daily symptom diary for the remote early detection of SARS-CoV-2 infections (COVID-RED): a structured summary of a study protocol for a randomized controlled trial.
Brakenhoff TB; Franks B; Goodale BM; van de Wijgert J; Montes S; Veen D; Fredslund EK; Rispens T; Risch L; Dowling AV; Folarin AA; Bruijning P; Dobson R; Heikamp T; Klaver P; Cronin M; Grobbee DE;
Trials; 2021 Jun; 22(1):412. PubMed ID: 34158099
[TBL] [Abstract][Full Text] [Related]
52. SARS-CoV-2 Omicron BA.5 Infections in Vaccinated Persons, Rural Uganda.
Mugisha J; Mpairwe B; Newton R; Cotten M; Phan MVT
Emerg Infect Dis; 2023 Jan; 29(1):224-226. PubMed ID: 36529453
[TBL] [Abstract][Full Text] [Related]
53. The Risk of Hospitalization and Mortality After Breakthrough SARS-CoV-2 Infection by Vaccine Type: Observational Study of Medical Claims Data.
Kshirsagar M; Nasir M; Mukherjee S; Becker N; Dodhia R; Weeks WB; Ferres JL; Richardson B
JMIR Public Health Surveill; 2022 Nov; 8(11):e38898. PubMed ID: 36265135
[TBL] [Abstract][Full Text] [Related]
54. Comparable cellular and humoral immunity upon homologous and heterologous COVID-19 vaccination regimens in kidney transplant recipients.
Körber N; Holzmann-Littig C; Wilkens G; Liao BH; Werz ML; Platen L; Cheng CC; Tellenbach M; Kappler V; Lehner V; Mijočević H; Christa C; Assfalg V; Heemann U; Schmaderer C; Protzer U; Braunisch MC; Bauer T; Renders L
Front Immunol; 2023; 14():1172477. PubMed ID: 37063863
[TBL] [Abstract][Full Text] [Related]
55. Longitudinal Severe Acute Respiratory Syndrome Coronavirus 2 Vaccine Antibody Responses and Identification of Vaccine Breakthrough Infections Among Healthcare Workers Using Nucleocapsid Immunoglobulin G.
Anderson M; Stec M; Gosha A; Mohammad T; Boler M; Tojo Suarez R; Behun D; Landay A; Cloherty G; Moy J
J Infect Dis; 2022 Nov; 226(11):1934-1942. PubMed ID: 36263799
[TBL] [Abstract][Full Text] [Related]
56. B- and T-Cell Responses After SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Receiving Disease Modifying Therapies: Immunological Patterns and Clinical Implications.
Iannetta M; Landi D; Cola G; Campogiani L; Malagnino V; Teti E; Coppola L; Di Lorenzo A; Fraboni D; Buccisano F; Grelli S; Mozzani M; Zingaropoli MA; Ciardi MR; Nisini R; Bernardini S; Andreoni M; Marfia GA; Sarmati L
Front Immunol; 2021; 12():796482. PubMed ID: 35111162
[TBL] [Abstract][Full Text] [Related]
57. Lower T cell response against SARS-CoV-2 variants of concern after mRNA vaccine and risk of breakthrough infections in people with HIV.
Casado JL; Vizcarra P; Martín-Colmenarejo S; Del Pino J; Gomez-Maldonado S; Martín-Hondarza A; Vallejo A
AIDS; 2023 May; 37(6):877-882. PubMed ID: 36779501
[TBL] [Abstract][Full Text] [Related]
58. Six-month sequelae of post-vaccination SARS-CoV-2 infection: A retrospective cohort study of 10,024 breakthrough infections.
Taquet M; Dercon Q; Harrison PJ
Brain Behav Immun; 2022 Jul; 103():154-162. PubMed ID: 35447302
[TBL] [Abstract][Full Text] [Related]
59. Immune responses to SARS-CoV-2 in vaccinated patients receiving checkpoint blockade immunotherapy for cancer.
Piening A; Ebert E; Khojandi N; Alspach E; Teague RM
Front Immunol; 2022; 13():1022732. PubMed ID: 36582225
[TBL] [Abstract][Full Text] [Related]
60. Seropositivity to Nucleoprotein to detect mild and asymptomatic SARS-CoV-2 infections: A complementary tool to detect breakthrough infections after COVID-19 vaccination?
van den Hoogen LL; Smits G; van Hagen CCE; Wong D; Vos ERA; van Boven M; de Melker HE; van Vliet J; Kuijer M; Woudstra L; Wijmenga-Monsuur AJ; GeurtsvanKessel CH; Stoof SP; Reukers D; Wijsman LA; Meijer A; Reusken CBEM; Rots NY; van der Klis FRM; van Binnendijk RS; den Hartog G
Vaccine; 2022 Apr; 40(15):2251-2257. PubMed ID: 35287986
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
